XML 142 R19.htm IDEA: XBRL DOCUMENT
v2.4.0.8

Segment Information | 12 Months Ended
--- | ---
Jun. 30, 2013
Segment Information | L. Segment Information: The Company has two reportable segments based on the nature of its products. R&D Systems’ Biotechnology Division, R&D Europe, Tocris, R&D China, BiosPacific and Boston Biochem are included in the biotechnology reporting segment. The Company’s biotechnology reporting segment develops, manufactures and sells biotechnology research and diagnostic products world-wide. The Company’s clinical controls reporting segment, which consists of R&D Systems’ Clinical Controls Division, develops and manufactures controls and calibrators for sale world-wide. No customer of either segment accounted for more than 10% of the Company’s consolidated net sales for the years ended June 30, 2013, 2012 and 2011. There are no concentrations of business transacted with a particular customer or supplier or concentrations of revenue from a particular product or geographic area that would severely impact the Company in the near term. The accounting policies of the segments are the same as those described in Note A. In evaluating segment performance, management focuses on sales and earnings before taxes. Following is financial information relating to the operating segments (in thousands):
|  | Year Ended June 30, |
|  | 2013 |  |  | 2012 |  |  | 2011 |
External sales |  |  |  |  |  |  |  |  |  |  |  |
Biotechnology |  | $ | 288,156 |  |  | $ | 293,274 |  |  | $ | 270,287 |
Clinical Controls |  |  | 22,419 |  |  |  | 21,286 |  |  |  | 19,675 |
Consolidated net sales |  | $ | 310,575 |  |  | $ | 314,560 |  |  | $ | 289,962 |
Earnings before taxes |  |  |  |  |  |  |  |  |  |  |  |
Biotechnology |  | $ | 156,910 |  |  | $ | 162,763 |  |  | $ | 164,332 |
Clinical Controls |  |  | 8,746 |  |  |  | 8,002 |  |  |  | 7,222 |
Segment earnings before taxes |  |  | 165,656 |  |  |  | 170,765 |  |  |  | 171,554 |
Other |  |  | (4,994 | ) |  |  | (8,570 | ) |  |  | (6,573 | )
Consolidated earnings before taxes |  | $ | 160,662 |  |  | $ | 162,195 |  |  | $ | 164,981 |
Goodwill |  |  |  |  |  |  |  |  |  |  |  |
Biotechnology |  | $ | 84,336 |  |  | $ | 85,682 |  |  | $ | 86,633 |
Clinical Controls |  |  | 0 |  |  |  | 0 |  |  |  | 0 |
Consolidated goodwill |  | $ | 84,336 |  |  | $ | 85,682 |  |  | $ | 86,633 |
Intangible assets, net |  |  |  |  |  |  |  |  |  |  |  |
Biotechnology |  | $ | 40,552 |  |  | $ | 46,476 |  |  | $ | 52,282 |
Clinical Controls |  |  | 0 |  |  |  | 0 |  |  |  | 0 |
Consolidated intangible assets, net |  | $ | 40,552 |  |  | $ | 46,476 |  |  | $ | 52,282 |
Assets |  |  |  |  |  |  |  |  |  |  |  |
Biotechnology |  | $ | 580,085 |  |  | $ | 529,392 |  |  | $ | 505,087 |
Clinical Controls |  |  | 24,887 |  |  |  | 22,135 |  |  |  | 21,046 |
Segment assets |  |  | 604,972 |  |  |  | 551,527 |  |  |  | 526,133 |
Other |  |  | 173,126 |  |  |  | 167,797 |  |  |  | 91,537 |
Consolidated assets |  | $ | 778,098 |  |  | $ | 719,324 |  |  | $ | 617,670 |
Depreciation and amortization |  |  |  |  |  |  |  |  |  |  |  |
Biotechnology |  | $ | 10,781 |  |  | $ | 10,920 |  |  | $ | 7,165 |
Clinical Controls |  |  | 389 |  |  |  | 411 |  |  |  | 417 |
Segment depreciation and amortization |  |  | 11,170 |  |  |  | 11,331 |  |  |  | 7,582 |
Other |  |  | 1,151 |  |  |  | 1,136 |  |  |  | 1,118 |
Consolidated depreciation and amortization |  | $ | 12,321 |  |  | $ | 12,467 |  |  | $ | 8,700 |
Capital purchases |  |  |  |  |  |  |  |  |  |  |  |
Biotechnology |  | $ | 3,248 |  |  | $ | 4,021 |  |  | $ | 2,707 |
Clinical Controls |  |  | 6,914 |  |  |  | 597 |  |  |  | 149 |
Segment capital purchases |  |  | 10,162 |  |  |  | 4,618 |  |  |  | 2,856 |
Other |  |  | 12,292 |  |  |  | 1,399 |  |  |  | 774 |
Consolidated capital purchases |  | $ | 22,454 |  |  | $ | 6,017 |  |  | $ | 3,630 |
The other reconciling items include the results of unallocated corporate expenses and assets, and the Company’s share of gain (losses) from its equity method investees. Following is financial information relating to geographic areas (in thousands):
|  | Year Ended June 30, |
|  | 2013 |  |  | 2012 |  |  | 2011 |
External sales |  |  |  |  |  |  |  |  |  |  |  |
United States |  | $ | 164,308 |  |  | $ | 172,310 |  |  | $ | 159,857 |
Europe |  |  | 88,297 |  |  |  | 90,142 |  |  |  | 83,676 |
China |  |  | 14,106 |  |  |  | 11,378 |  |  |  | 8,299 |
Other Asia |  |  | 28,608 |  |  |  | 25,988 |  |  |  | 24,715 |
Rest of world |  |  | 15,256 |  |  |  | 14,742 |  |  |  | 13,415 |
Total external sales |  | $ | 310,575 |  |  | $ | 314,560 |  |  | $ | 289,962 |
Long-lived assets |  |  |  |  |  |  |  |  |  |  |  |
United States |  | $ | 103,541 |  |  | $ | 87,968 |  |  | $ | 88,802 |
Europe |  |  | 7,129 |  |  |  | 7,528 |  |  |  | 7,819 |
China |  |  | 117 |  |  |  | 141 |  |  |  | 96 |
Total long-lived assets |  | $ | 110,787 |  |  | $ | 95,637 |  |  | $ | 96,717 |
External sales are attributed to countries based on the location of the customer/distributor. Long-lived assets are comprised of land, buildings and improvements and equipment, net of accumulated depreciation and other assets.

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8380-108599 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8933-108599 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8538-108599 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 26 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8844-108599 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 29 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8864-108599 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 34 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8981-108599 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 35 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8984-108599 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9038-108599 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599 Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9054-108599 Reference 11: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8924-108599 Reference 12: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9031-108599 Reference 13: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 33 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8971-108599 Reference 14: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 12 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8595-108599 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration